PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (0.03% Proclin)

Catalog # C13-PCFMY2





Source

Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) is expressed from human HEK293 cells, which provides higher batch consistency and long term security of supply.

Application

Flow Cytometry (Evaluation of Anti-BCMA (C11D5.3 scFv) CAR Expression).

Clone

3G8C1

Species

Mouse

Isotype

Mouse IgG1 | Mouse kappa

Specificity

Specifically recognizes the antigen-recognition domain of C11D5.3 derived CARs.

Immunogen

Recombinant C11D5.3 scFv derived from HEK293 cells.

Conjugate

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

Isotype Control

The Isotype control is sold separately and you can search for Cat. No. <u>DNP-PM1</u> for product information.

Recommended Dilution

1:50

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4, 0.2% BSA, 0.03% Proclin 300 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.


Storage

Please protect from light and avoid repeated freeze-thaw cycles.


This product is stable after storage at:


- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months after reconstitution.
- 2-8 °C for 12 months after reconstitution.

Bioactivity-FACS



Flow cytometric analysis of Anti-BCMA(C11D5.3) CAR-293 cells staining with PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (Cat. No. C13-PCFMY2) at 1:50 dilution (2 μL of the antibody stock





Non-specificity of PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (Cat. No. C13-PCFMY2) binding to CD3+ cells present in human PBMC. 5e5 of human PBMCs were simultaneously stained with



PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (0.03% Proclin)


Catalog # C13-PCFMY2



solution corresponds to labeling of 1e6 cells in a final volume of $100 \mu L$), compared with Isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).

FITC-Labeled Monoclonal Anti-Human CD3 Antibody and PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (2 μ L of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 μ L) and washed and then analyzed with FACS. Both FITC and PE positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).

Compared Data



Flow cytometric analysis of Anti-BCMA (C11D5.3) CAR-293 cells staining with PE-Labeled Monoclonal Anti-C11D5.3 scFv Antibodies. PE signal was used to evaluate the binding activity of anti-C11D5.3 scFv antibody. The biological activity level of C13-PCFMY2 is superior to Competitor B (Routinely tested).

Background

C11D5.3 is an IgG1 mouse monoclonal antibody specific for BCMA, which is a target for the immunotherapy of multiple myeloma and lymphomas. C11D5.3 scFv is the most commonly used ectodomain componse of BCMA-specific CARs. So far, multiple reported CART BCMA trials contain the anti-BCMA scFv derived from C11D5.3, such as FDA approved CARs Abecma.

Clinical and Translational Updates

